Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey
- 11 July 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 33 (12), 2241-2247
- https://doi.org/10.1007/s10096-014-2194-8
Abstract
This is the first Portuguese multicenter observational and descriptive study that provides insights on the species distribution and susceptibility profiles of yeast isolates from fungemia episodes. Ten district hospitals across Portugal contributed by collecting yeast isolates from blood cultures and answering questionnaires concerning patients’ data during a 12-month period. Molecular identification of cryptic species of Candida parapsilosis and C. glabrata complex was performed. The susceptibility profile of each isolate, considering eight of the most often used antifungals, was determined. Both Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) protocols were applied. The incidence of 240 episodes of fungemia was 0.88/1,000 admissions. Fifteen different species were found, with C. albicans (40 %) being the most prevalent, followed by C. parapsilosis (23 %) and C. glabrata (13 %). Most isolates were recovered from patients admitted to surgical wards or intensive care units, with 57 % being males and 32 % aged between 41 and 60 years. For both the CLSI and EUCAST protocols, the overall susceptibility rates ranged from 74 to 97 % for echinocandins and from 84 to 98 % for azoles. Important resistance rate discrepancies between protocols were observed in C. albicans and C. glabrata for echinocandins and in C. parapsilosis and C. tropicalis for azoles. Death associated with fungemia occurred in 25 % of the cases, with more than half of C. glabrata infections being fatal. The great number of Candida non-albicans is noteworthy despite a relatively low antifungal resistance rate. Studies like this are essential in order to improve empirical treatment guidelines.Keywords
This publication has 27 references indexed in Scilit:
- Candidemia: incidence rates, type of species, and risk factors at a tertiary care academic hospital in ChinaInternational Journal of Infectious Diseases, 2014
- Epidemiology and risk factors for invasive candidiasisTherapeutics and Clinical Risk Management, 2014
- Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?Antimicrobial Agents and Chemotherapy, 2013
- Distribution, virulence attributes and antifungal susceptibility patterns ofCandida parapsilosiscomplex strains isolated from clinical samplesMedical Mycology, 2013
- Candidaemia in Sweden: a nationwide prospective observational surveyClinical Microbiology & Infection, 2013
- Nationwide Study of Candidemia, Antifungal Use, and Antifungal Drug Resistance in Iceland, 2000 to 2011Journal of Clinical Microbiology, 2013
- Looking for Candida nivariensis and C. bracarensis among a large Italian collection of C. glabrata isolates: results of the FIMUA working groupMycoses, 2012
- Epidemiology and management of candidaemia - a retrospective, multicentre study in five hospitals in the UKMycoses, 2011
- A first Portuguese epidemiological survey of fungaemia in a university hospitalEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- Candida orthopsilosis and Candida metapsilosis spp. nov. To Replace Candida parapsilosis Groups II and IIIJournal of Clinical Microbiology, 2005